Nib's Valuation Appeal Offset by Margin Risks -- Market Talk
Dow Jones
Feb 24
0003 GMT - Nib's valuation appeals to UBS analysts, but they stay cautious on the Australian health insurer due to rising margin risks. Maintaining a neutral rating on the stock, the UBS analysts tell clients in a note that earnings visibility surrounding Nib's key Australian residents business has become more opaque due to softer policy growth and accelerating claims-paid inflation. Margin risks look skewed to the downside despite the insurer's tighter cost control, they add. UBS trims its target price 1.4% to A$7.20. Shares are down 2.5% at A$6.36. (stuart.condie@wsj.com)
(END) Dow Jones Newswires
February 23, 2026 19:03 ET (00:03 GMT)
Copyright (c) 2026 Dow Jones & Company, Inc.
At the request of the copyright holder, you need to log in to view this content
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.